Healthcare >> CEO Interviews >> October 5, 2000
JACK W. REICH, PhD is currently the Chief Executive Officer and Chairman
of the Board for Collateral Therapeutics, Inc. The company is a leader
in the field of cardiovascular gene therapy and went public in July
1998. Dr. Reich also co-founded MyoTech, Inc., a venture based upon a
novel clinical service model and drug therapy to treat chronic muscle
injury. That company was sold in 1996. Dr. Reich was also a General
Partner of Cabrillo Partners, a San Diego-based business development
company created to develop start-up and early-stage companies focused in
the areas of health care, medicine, biotechnology, and life sciences.
Prior to forming Cabrillo Partners, Dr. Reich was Senior Vice President
of Enterprise Partners, a successful, southern California-based venture
capital firm, and has played a key role in developing biotech and
medical technology companies. Prior to his career in venture capital,
Dr. Reich was Vice President, Regulatory Affairs and Quality Operations
at Gensia, Inc., a biopharmaceutical company formed to discover,
develop, manufacture, and market novel pharmaceutical products for the
diagnosis and treatment of human disease. During his long career in the
pharmaceutical industry, Dr. Reich has had extensive experience and
interaction with regulatory bodies, including the FDA, and has been
responsible for FDA approval and the successful introduction of a broad
range of new drugs. Dr. Reich has a Bachelor of Arts degree in Biology
from Washington and Jefferson College, a Bachelor of Science degree in
Pharmacy from Creighton University, a Master of Science degree in
Hospital Pharmacy Administration from Temple University, and a PhD in
Pharmaceuticals-International Pharmaceutical Administration from Temple
University. Profile
Therapeutics, Inc.?
Dr. Reich: Collateral Therapeutics is five years old. It's a
cardiovascular gene therapy company that
